Tesofensine Research & Studies
We track 20 published, PubMed-indexed studies for Tesofensine, spanning 2007 to 2018. The research below includes 10 reviews, 9 clinical trials, 1 meta-analysis.
These summaries are for educational purposes. Research findings, particularly from preclinical studies, may not translate to human outcomes. Always consult a qualified healthcare provider before making decisions based on this information.
10
Reviews
9
Clinical Trials
1
Meta-Analysis
Centrally Acting Agents for Obesity: Past, Present, and Future.
ReviewCoulter AA, Rebello CJ, Greenway FL|Drugs|2018
Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.
ReviewSrivastava G, Apovian C|Curr Obes Rep|2018
Approaches for the Development of Drugs for Treatment of Obesity and Metabolic Syndrome.
ReviewMaksimov ML, Svistunov AA, et al.|Curr Pharm Des|2016
New and emerging drug molecules against obesity.
ReviewGeorge M, Rajaram M, Shanmugam E|J Cardiovasc Pharmacol Ther|2014
Dopamine reuptake transporter (DAT) "inverse agonism"--a novel hypothesis to explain the enigmatic pharmacology of cocaine.
ReviewHeal DJ, Gosden J, Smith SL|Neuropharmacology|2014
The effect of tesofensine on appetite sensations.
Clinical TrialGilbert JA, Gasteyger C, et al.|Obesity (Silver Spring)|2012
Anti-obesity drugs: a review about their effects and their safety.
ReviewDerosa G, Maffioli P|Expert Opin Drug Saf|2012
Neuropsychiatric adverse effects of centrally acting antiobesity drugs.
ReviewNathan PJ, O'Neill BV, et al.|CNS Neurosci Ther|2011
Serotonergic anti-obesity agents: past experience and future prospects.
ReviewHalford JC, Boyland EJ, et al.|Drugs|2011
Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users.
Clinical TrialSchoedel KA, Meier D, et al.|Clin Pharmacol Ther|2010
Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.
Clinical TrialLehr T, Staab A, et al.|AAPS J|2010
The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men.
Clinical TrialSjödin A, Gasteyger C, et al.|Int J Obes (Lond)|2010
Pharmacological management of appetite expression in obesity.
ReviewHalford JC, Boyland EJ, et al.|Nat Rev Endocrinol|2010
[Recent progress and novel perspectives on obesity pharmacotherapy].
ReviewFaria AM, Mancini MC, et al.|Arq Bras Endocrinol Metabol|2010
A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam.
Clinical TrialLehr T, Staab A, et al.|Clin Pharmacokinet|2009
Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease.
Meta-AnalysisAstrup A, Meier DH, et al.|Obesity (Silver Spring)|2008
Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study.
Clinical TrialRascol O, Poewe W, et al.|Arch Neurol|2008
Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.
Clinical TrialAstrup A, Madsbad S, et al.|Lancet|2008
Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease.
Clinical TrialLehr T, Staab A, et al.|Br J Clin Pharmacol|2007
Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease.
Clinical TrialHauser RA, Salin L, et al.|Mov Disord|2007